Name: 글로벌 시장 동향
SKU: PH1050
Availability: InStock

보고서 요약(국문)

보고서 개요
전 세계 발기부전 치료제 시장은 2023년 35억 달러 규모에 달했으며, 2024년부터 2031년까지 연평균 4.7% 성장하여 2031년에는 50억 달러에 이를 것으로 예상됩니다.
발기부전(ED)은 모든 연령대의 남성, 특히 노년층에게 흔히 발생하는 질환입니다. 심혈관 질환, 당뇨병, 비만, 호르몬 불균형, 스트레스, 불안, 우울증과 같은 신체적, 심리적 요인이 원인이 될 수 있습니다. 흡연, 과도한 음주, 운동 부족과 같은 생활 습관 또한 발기부전을 악화시킬 수 있습니다.
시장 동향: 성장 동인 및 제약 요인
발기부전 유병률 증가
발기부전은 당뇨병, 고콜레스테롤, 흡연, 스트레스, 정신 건강 문제와 같은 신체적, 심리적 요인으로 인해 남성이 발기를 유지하는 데 어려움을 겪는 질환입니다.

예를 들어, 세계보건기구(WHO) 보고서에 따르면 매년 남성의 15%가 자궁내막증(ED)의 영향을 받고 있으며, 2025년에는 그 수가 3,200억 건에 달할 것으로 예상됩니다. ED는 테스토스테론 수치의 자연적인 감소, 혈류량 감소, 그리고 노화 관련 생리적 변화로 인해 특히 노년 남성에게 흔하게 나타납니다. 노년층은 당뇨병, 심혈관 질환, 고혈압과 같은 만성 질환을 앓을 가능성이 더 높으며, 이러한 질환들은 ED의 주요 위험 요인입니다. 2023년 세계 사회 보고서는 2050년까지 세계 인구가 16억 명에 이를 것으로 예측하며, 이는 남성 ED 유병률을 더욱 증가시킬 것입니다.

약물 관련 과제
전 세계 발기부전 치료제 시장은 제네릭 의약품의 출시, 질환에 대한 사회적 낙인, 잠재적인 부작용, 그리고 한방 요법 및 생활 습관 변화와 같은 대체 요법의 등장 등 여러 가지 과제에 직면해 있습니다. 이러한 요인들은 시장 성장을 저해하고 경쟁 심화 및 약가 하락으로 이어질 수 있습니다.

또한, 발기부전과 관련된 사회적 낙인은 남성들이 치료를 받는 것을 꺼리게 하여 보고 누락 및 진단 부족으로 이어질 수 있습니다. 따라서 이러한 요인들이 복합적으로 작용하여 전 세계 발기부전 치료제 시장에 상당한 어려움을 초래합니다.
시장 세분화 분석
전 세계 발기부전 치료제 시장은 약물 종류, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
약물 종류 중 PDE5 억제제는 발기부전 치료제 시장 점유율의 약 41.3%를 차지했습니다.
비아그라, 시알리스, 레비트라와 같은 포스포디에스테라제 5형(PDE5) 억제제는 입증된 효능과 안전성으로 인해 발기부전(ED) 치료에 가장 일반적으로 처방되는 약물입니다.
이러한 약물은 음경으로의 혈류를 증가시켜 성적 자극에 대한 반응으로 발기를 유도합니다. 강력한 임상적 근거, 간편한 경구 투여, 그리고 긍정적인 환자 결과에 힘입어 널리 사용되고 있습니다. 브랜드 의약품과 제네릭 의약품 모두 출시되면서 접근성이 향상되었습니다. 새로운 치료법과의 경쟁에도 불구하고 PDE5 억제제는 전 세계적으로 발기부전 치료의 핵심으로 자리 잡고 있습니다.
예를 들어, 2024년 6월, 바이오제약 회사인 팔라틴 테크놀로지스(Palatin Technologies)는 멜라노코르틴 4 수용체 억제제인 브레멜라노티드(BMT)와 포스포디에스테라제 5 억제제(PDE5i)를 병용 투여하는 발기부전 치료 2상 임상 연구를 시작했습니다.
시장 지역 분석
북미는 예측 기간 동안 전체 시장 점유율의 약 38.4%를 차지할 것으로 예상됩니다.
북미는 신약 승인, 의료 기술의 발전으로 더욱 효과적이고 편리한 치료 옵션이 제공됨에 따라 더 많은 사람들이 치료를 받도록 유도하고 발기부전 치료제 시장을 확대하면서 예측 기간 동안 전체 시장 점유율의 약 38.4%를 차지할 것으로 예상됩니다.

예를 들어, 2024년 2월 페트로스 제약(Petros Pharmaceuticals)과 23andMe는 주요 AI 소프트웨어 제공업체와 협력하여 STENDRA(아바나필)의 일반의약품(OTC) 승인을 위한 자가 선택 연구에 첨단 기술을 통합했습니다. 이 AI 기반 도구는 선별 정확도를 향상시키고, FDA 및 ACNU 가이드라인에 따라 안전한 의약품 접근을 보장하며, 페트로스의 OTC 승인 절차를 강화하는 것을 목표로 했습니다.
또한, 2023년 6월 FDA는 발기부전 치료제인 MED3000(Eroxon)의 일반의약품 판매를 승인했습니다. 이 젤은 일반적인 발기부전 치료제보다 효과가 더 빠를 수 있으며, 일회용 튜브에 담겨 있습니다.

시장 세분화
약물 종류별
PDE5 억제제
테스토스테론 대체 요법
알프로스타딜
복합제
투여 경로별
경구
주사제
국소제
기타
유통 채널별
병원 약국
소매 약국
온라인 약국
지역별
북미
미국
캐나다
멕시코
유럽
독일
영국
프랑스
이탈리아
스페인
기타 유럽
남미
브라질
아르헨티나
기타 남미
아시아 태평양
중국
인도
일본
한국
기타 아시아 태평양
중동 및 아프리카
시장 경쟁 환경
주요 글로벌 시장 참여 기업으로는 Pfizer Inc., Eli Lilly and Company, Bayer AG, GlaxoSmithKline plc, Johnson & Johnson, Therapeutics MD, Inc., VIVUS, Inc. 등이 있습니다. 메나리니 그룹, 메디스프라우트, 아스텔라스 파마 등이 주요 기업입니다.
주요 동향
2023년 5월, 힘스앤허스 헬스(Hims & Hers Health, Inc.)는 미국에서 발기부전 치료용 츄어블 민트향 정제인 '하드 민트(Hard Mints)'를 출시했습니다. 영국에서는 6월부터 판매될 예정입니다. 비아그라, 시알리스, 레비트라 등의 유효 성분을 활용하여, 고객 만족도가 높은 맞춤형 솔루션을 제공하고, 자사의 원격 의료 플랫폼을 통해 편리하게 이용할 수 있도록 지원하는 것을 목표로 합니다.
보고서 구매 이유
약물 종류, 투여 경로, 유통 채널, 지역별 글로벌 발기부전 치료제 시장 세분화 현황을 시각화하고, 주요 기업 및 주요 업체를 파악하기 위함입니다.

트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴할 수 있습니다.
모든 세그먼트를 포함한 발기부전 치료제 시장의 다양한 데이터가 담긴 엑셀 시트가 제공됩니다.

심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서입니다.

보고서는 모든 세그먼트에 대한 데이터를 포함하고 있습니다. 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료를 엑셀 파일로 제공합니다.
글로벌 발기부전 치료제 시장 보고서는 약 64개의 표, 61개의 그림, 그리고 186페이지 분량으로 구성됩니다.
주요 고객 (2024년 기준)
제조업체/구매자
산업 투자자/투자은행가
연구 전문가
신흥 기업

보고서 요약(영어 원문)

Report Overview
Global Erectile Dysfunction Drugs Market reached US$ 3.5 billion in 2023 and is expected to reach US$ 5.0 billion by 2031, growing at a CAGR of 4.7% during the forecast period 2024-2031.
Erectile dysfunction (ED) is a common condition affecting men of all ages, particularly older individuals. It can be caused by physical and psychological factors, such as cardiovascular disease, diabetes, obesity, hormonal imbalances, stress, anxiety, and depression. Lifestyle choices like smoking, excessive alcohol consumption, and lack of exercise can also contribute to ED.
Market Dynamics: Drivers & Restraints
Increasing prevalence of erectile dysfunction
ED is a condition where men struggle to maintain a penile erection due to physical and psychological issues like diabetes, high cholesterol, smoking, stress, and mental health.
For instance, according to World Health Organization (WHO) reports that 15% of men are affected by endometriosis (ED) each year, with a projected 320 billion cases by 2025. ED is particularly prevalent in geriatric men due to a natural decline in testosterone levels, reduced blood flow, and age-related physiological changes. The geriatric population is more likely to have chronic conditions like diabetes, cardiovascular disease, and hypertension, which are major risk factors for ED. The World Social Report 2023 predicts a global population of 1.6 billion by 2050, further increasing the prevalence of ED in men.
Challenges associated with the drugs
The global erectile dysfunction drugs market faces several challenges, including the availability of generic versions, stigma associated with the condition, potential side effects, and the rise of alternative therapies like herbal remedies and lifestyle changes. These factors can hinder the market's growth, leading to increased competition and reduced drug prices.
Additionally, the stigma associated with the condition can discourage men from seeking treatment, leading to underreporting and underdiagnosis. Therefore, these factors collectively pose a significant challenge to the global erectile dysfunction drugs market.
Market Segment Analysis
The global erectile dysfunction drugs market is segmented based on drug class, route of administration, distribution channel, and region.
The PDE5 Inhibitors from the drug class segment accounted for approximately 41.3% of the erectile dysfunction drugs market share
The PDE5 inhibitors from the drug class segment accounted for approximately 41.3%. Phosphodiesterase type 5 (PDE5) inhibitors, such as Viagra, Cialis, and Levitra, are the most commonly prescribed treatments for erectile dysfunction (ED) due to their proven efficacy and safety.
These drugs enhance blood flow to the penis, facilitating an erection in response to sexual stimulation. Their widespread adoption is driven by strong clinical evidence, ease of oral administration, and favorable patient outcomes. The availability of both branded and generic versions has made them more accessible. Despite competition from newer treatments, PDE5 inhibitors remain the cornerstone of ED management worldwide.
For instance, in June 2024, Palatin Technologies, a biopharmaceutical company, initiated a Phase 2 clinical study for erectile dysfunction treatment using bremelanotide (BMT), a melanocortin 4 receptor co-administered with a phosphodiesterase 5 inhibitor (PDE5i).
Market Geographical Analysis
North America is estimated to hold about 38.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to novel drug approvals, advancements in medical technology have led to more effective and convenient treatment options, encouraging more individuals to seek treatment and expanding the market for ED drugs.
For instance, in February 2024, Petros Pharmaceuticals and 23andMe partnered with a major AI software provider to integrate advanced technology into its Self-Selection Study for STENDRA (avanafil) OTC approval. The AI-driven tool aimed to improve screening accuracy, ensure safe access to medication under FDA & ACNU guidelines, and enhance Petros' pathway toward OTC status.
Moreover, in June 2023, the FDA approved the over-the-counter sale of MED3000 (Eroxon), a topical gel that treats ED and may work faster than regular ED medication. The gel comes in a single-use tube.
Market Segmentation
By Drug Class
PDE5 Inhibitors
Testosterone Replacement Therapy
Alprostadil
Combination Drugs
By Route of Administration
Oral
Injectable
Topical
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
The U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major global players in the market include Pfizer Inc., Eli Lilly and Company, Bayer AG, GlaxoSmithKline plc, Johnson & Johnson, Therapeutics MD, Inc., VIVUS, Inc., Menarini Group, MediSprout, Astellas Pharma Inc among others.
Key Developments
In May 2023, Hims & Hers Health, Inc. launched Hard Mints, chewable mint-flavored tablets for treating sexual dysfunction, in the U.S. They will be available in the UK starting in June. Leveraging active ingredients such as Viagra, Cialis, & Levitra, they aim to offer a personalized and discreet solution backed by positive customer feedback and facilitated through their telehealth platform.
Why Purchase the Report?
To visualize the global erectile dysfunction drugs market segmentation based on drug class, route of administration, distribution channel, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the erectile dysfunction drugs market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.
The global erectile dysfunction drugs market report would provide approximately 64 tables, 61 figures, and 186 pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Class
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in prevalence of erectile dysfunction
4.1.1.2. Novel approach for new drugs
4.1.2. Restraints
4.1.2.1. Challenges associated with the drugs
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. PESTLE Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. By Drug Class
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
6.1.2. Market Attractiveness Index, By Drug Class
6.2. PDE5 Inhibitors*
6.2.1. Introduction
6.3. Testosterone Replacement Therapy
6.4. Alprostadil
6.5. Combination Drugs
7. By Route of Administration
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.2. Market Attractiveness Index, By Route of Administration
7.3. Oral*
7.3.1. Introduction
7.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.4. Injectable
7.5. Topical
7.6. Others
8. By Distribution Channel
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacies*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacies
8.4. Online Pharmacies
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. The U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. UK
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Pfizer Inc*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Eli Lilly and Company
11.3. Bayer AG
11.4. GlaxoSmithKline plc
11.5. Johnson & Johnson
11.6. Therapeutics MD, Inc
11.7. VIVUS, Inc.
11.8. Menarini Group
11.9. MediSprout
11.10. Astellas Pharma Inc (*LIST NOT EXHAUSTIVE)
12. Appendix
12.1. About Us and Services
12.2. Contact Us

언급된 주요 기업들

Pfizer Inc, 4.	Key Developments, Eli Lilly and Company, Bayer AG, GlaxoSmithKline plc, Johnson & Johnson, Therapeutics MD, Inc, VIVUS, Inc., Menarini Group, MediSprout

표 목록 (Tables)

List of Tables

Table 1 Global Erectile Dysfunction Drugs Market Value, By Drug Class, 2023, 2027 & 2031 (US$ Billion)

Table 2 Global Erectile Dysfunction Drugs Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Billion)

Table 3 Global Erectile Dysfunction Drugs Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Billion)

Table 4 Global Erectile Dysfunction Drugs Market Value, By Region, 2023, 2027 & 2031 (US$ Billion)

Table 5 Global Erectile Dysfunction Drugs Market Value, By Drug Class, 2023, 2027 & 2031 (US$ Billion)

Table 6 Global Erectile Dysfunction Drugs Market Value, By Drug Class, 2022-2031 (US$ Billion)

Table 7 Global Erectile Dysfunction Drugs Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Billion)

Table 8 Global Erectile Dysfunction Drugs Market Value, By Route of Administration, 2022-2031 (US$ Billion)

Table 9 Global Erectile Dysfunction Drugs Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Billion)

Table 10 Global Erectile Dysfunction Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Billion)

Table 11 Global Erectile Dysfunction Drugs Market Value, By Region, 2023, 2027 & 2031 (US$ Billion)

Table 12 Global Erectile Dysfunction Drugs Market Value, By Region, 2022-2031 (US$ Billion)

Table 13 North America Erectile Dysfunction Drugs Market Value, By Drug Class, 2022-2031 (US$ Billion)

Table 14 North America Erectile Dysfunction Drugs Market Value, By Route of Administration, 2022-2031 (US$ Billion)

Table 15 North America Erectile Dysfunction Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Billion)

Table 16 North America Erectile Dysfunction Drugs Market Value, By Country, 2022-2031 (US$ Billion)

Table 17 Asia-Pacific Erectile Dysfunction Drugs Market Value, By Drug Class, 2022-2031 (US$ Billion)

Table 18 Asia-Pacific Erectile Dysfunction Drugs Market Value, By Route of Administration, 2022-2031 (US$ Billion)

Table 19 Asia-Pacific Erectile Dysfunction Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Billion)

Table 20 Asia-Pacific Erectile Dysfunction Drugs Market Value, By Country, 2022-2031 (US$ Billion)

Table 21 Europe Erectile Dysfunction Drugs Market Value, By Drug Class, 2022-2031 (US$ Billion)

Table 22 Europe Erectile Dysfunction Drugs Market Value, By Route of Administration, 2022-2031 (US$ Billion)

Table 23 Europe Erectile Dysfunction Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Billion)

Table 24 Europe Erectile Dysfunction Drugs Market Value, By Country, 2022-2031 (US$ Billion)

Table 25 South America Erectile Dysfunction Drugs Market Value, By Drug Class, 2022-2031 (US$ Billion)

Table 26 South America Erectile Dysfunction Drugs Market Value, By Route of Administration, 2022-2031 (US$ Billion)

Table 27 South America Erectile Dysfunction Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Billion)

Table 28 South America Erectile Dysfunction Drugs Market Value, By Country, 2022-2031 (US$ Billion)

Table 29 Middle East and Africa Erectile Dysfunction Drugs Market Value, By Drug Class, 2022-2031 (US$ Billion)

Table 30 Middle East and Africa Erectile Dysfunction Drugs Market Value, By Route of Administration, 2022-2031 (US$ Billion)

Table 31 Middle East and Africa Erectile Dysfunction Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Billion)

Table 32 Middle East and Africa Erectile Dysfunction Drugs Market Value, By Country, 2022-2031 (US$ Billion)

Table 33 Pfizer Inc.: Overview

Table 34 Pfizer Inc.: Product Portfolio

Table 35 Pfizer Inc.: Key Developments

Table 36 Eli Lilly and Company: Overview

Table 37 Eli Lilly and Company: Product Portfolio

Table 38 Eli Lilly and Company: Key Developments

Table 39 Bayer AG: Overview

Table 40 Bayer AG: Product Portfolio

Table 41 Bayer AG: Key Developments

Table 42 GlaxoSmithKline plc: Overview

Table 43 GlaxoSmithKline plc: Product Portfolio

Table 44 GlaxoSmithKline plc: Key Developments

Table 45 Johnson & Johnson: Overview

Table 46 Johnson & Johnson: Product Portfolio

Table 47 Johnson & Johnson: Key Developments

Table 48 TherapeuticsMD, Inc.: Overview

Table 49 TherapeuticsMD, Inc.: Product Portfolio

Table 50 TherapeuticsMD, Inc.: Key Developments

Table 51 VIVUS, Inc.: Overview

Table 52 VIVUS, Inc.: Product Portfolio

Table 53 VIVUS, Inc.: Key Developments

Table 54 Menarini Group: Overview

Table 55 Menarini Group: Product Portfolio

Table 56 Menarini Group: Key Developments

Table 57 MediSprout: Overview

Table 58 MediSprout: Product Portfolio

Table 59 MediSprout: Key Developments

Table 60 Astellas Pharma Inc: Overview

Table 61 Astellas Pharma Inc: Product Portfolio

Table 62 Astellas Pharma Inc: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Erectile Dysfunction Drugs Market Value, 2022-2031 (US$ Billion)

Figure 2 Global Erectile Dysfunction Drugs Market Share, By Drug Class, 2023 & 2031 (%)

Figure 3 Global Erectile Dysfunction Drugs Market Share, By Route of Administration, 2023 & 2031 (%)

Figure 4 Global Erectile Dysfunction Drugs Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 5 Global Erectile Dysfunction Drugs Market Share, By Region, 2023 & 2031 (%)

Figure 6 Global Erectile Dysfunction Drugs Market Y-o-Y Growth, By Drug Class, 2023-2031 (%)

Figure 7 PDE5 Inhibitors Erectile Dysfunction Drugs Market Value, 2022-2031 (US$ Billion)

Figure 8 Testosterone Replacement Therapy Erectile Dysfunction Drugs Market Value, 2022-2031 (US$ Billion)

Figure 9 Alprostadil Erectile Dysfunction Drugs Market Value, 2022-2031 (US$ Billion)

Figure 10 Combination Drugs Erectile Dysfunction Drugs Market Value, 2022-2031 (US$ Billion)

Figure 11 Global Erectile Dysfunction Drugs Market Y-o-Y Growth, By Route of Administration, 2023-2031 (%)

Figure 12 Oral Route of Administration in Global Erectile Dysfunction Drugs Market Value, 2022-2031 (US$ Billion)

Figure 13 Injectable Route of Administration in Global Erectile Dysfunction Drugs Market Value, 2022-2031 (US$ Billion)

Figure 14 Topical Route of Administration in Global Erectile Dysfunction Drugs Market Value, 2022-2031 (US$ Billion)

Figure 15 Others Route of Administration in Global Erectile Dysfunction Drugs Market Value, 2022-2031 (US$ Billion)

Figure 16 Global Erectile Dysfunction Drugs Market Y-o-Y Growth, By Distribution Channel, 2023-2031 (%)

Figure 17 Hospital Pharmacies Distribution Channel in Global Erectile Dysfunction Drugs Market Value, 2022-2031 (US$ Billion)

Figure 18 Retail Pharmacies Distribution Channel in Global Erectile Dysfunction Drugs Market Value, 2022-2031 (US$ Billion)

Figure 19 Online Pharmacies Distribution Channel in Global Erectile Dysfunction Drugs Market Value, 2022-2031 (US$ Billion)

Figure 20 Global Erectile Dysfunction Drugs Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 21 North America Erectile Dysfunction Drugs Market Value, 2022-2031 (US$ Billion)

Figure 22 North America Erectile Dysfunction Drugs Market Share, By Drug Class, 2023 & 2031 (%)

Figure 23 North America Erectile Dysfunction Drugs Market Share, By Route of Administration, 2023 & 2031 (%)

Figure 24 North America Erectile Dysfunction Drugs Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 25 North America Erectile Dysfunction Drugs Market Share, By Country, 2023 & 2031 (%)

Figure 26 Asia-Pacific Erectile Dysfunction Drugs Market Value, 2022-2031 (US$ Billion)

Figure 27 Asia-Pacific Erectile Dysfunction Drugs Market Share, By Drug Class, 2023 & 2031 (%)

Figure 28 Asia-Pacific Erectile Dysfunction Drugs Market Share, By Route of Administration, 2023 & 2031 (%)

Figure 29 Asia-Pacific Erectile Dysfunction Drugs Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 30 Asia-Pacific Erectile Dysfunction Drugs Market Share, By Country, 2023 & 2031 (%)

Figure 31 Europe Erectile Dysfunction Drugs Market Value, 2022-2031 (US$ Billion)

Figure 32 Europe Erectile Dysfunction Drugs Market Share, By Drug Class, 2023 & 2031 (%)

Figure 33 Europe Erectile Dysfunction Drugs Market Share, By Route of Administration, 2023 & 2031 (%)

Figure 34 Europe Erectile Dysfunction Drugs Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 35 Europe Erectile Dysfunction Drugs Market Share, By Country, 2023 & 2031 (%)

Figure 36 South America Erectile Dysfunction Drugs Market Value, 2022-2031 (US$ Billion)

Figure 37 South America Erectile Dysfunction Drugs Market Share, By Drug Class, 2023 & 2031 (%)

Figure 38 South America Erectile Dysfunction Drugs Market Share, By Route of Administration, 2023 & 2031 (%)

Figure 39 South America Erectile Dysfunction Drugs Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 40 South America Erectile Dysfunction Drugs Market Share, By Country, 2023 & 2031 (%)

Figure 41 Middle East and Africa Erectile Dysfunction Drugs Market Value, 2022-2031 (US$ Billion)

Figure 42 Middle East and Africa Erectile Dysfunction Drugs Market Share, By Drug Class, 2023 & 2031 (%)

Figure 43 Middle East and Africa Erectile Dysfunction Drugs Market Share, By Route of Administration, 2023 & 2031 (%)

Figure 44 Middle East and Africa Erectile Dysfunction Drugs Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 45 Pfizer Inc.: Financials

Figure 46 Eli Lilly and Company: Financials

Figure 47 Bayer AG: Financials

Figure 48 GlaxoSmithKline plc: Financials

Figure 49 Johnson & Johnson: Financials

Figure 50 TherapeuticsMD, Inc.: Financials

Figure 51 VIVUS, Inc.: Financials

Figure 52 Menarini Group: Financials

Figure 53 MediSprout: Financials

Figure 54 Astellas Pharma Inc: Financials

세계 발기부전 치료제 시장 – 2024년 – 2031년

Global Erectile Dysfunction Drugs Market - 2024 - 2031